IMPACT ON DLQI OF A MODIFIED IMMUNOCORRECTIVE COMPLEX TREATMENT DEVELOPED USING AN EXCIMER LASER FOR PATIENTS WITH VITILIGO.

Abstract

For the period from 2020 to 2023, 118 patients (Group I (main group) n=60, Group II (comparison group) n=58) from patients with two clinical forms of vitiligo were examined. The study included patients of both sexes: 66 women and 52 men, aged 18 to 75 years (mean age 38.5 ± 6.8 years). In Group I (n=60), patients received combined phototherapy with narrow-band UVB therapy at 311 nm and therapy with an excimer laser with a length of 308 nm and, in addition, pentaxophylline, a minipulse corticosteroid therapy (dexamethasone) with topical therapy of 0.1% tacrolimus ointment. Group II (comparison group), where patients received combined phototherapy - narrow-band UVB therapy 311 nm and therapy with an excimer laser with a length of 308 nm. and topical therapy with tacrolimus ointment. It also greatly affects the dermatology life quality index (DLQI) of vitiligo patients.Before treatment, the mean value of DIQ was 10.9 ± 3.7 and 10.6 ± 2.0 points in both groups, which, according to the assessment scale, corresponds to a strong negative effect of the disease on the life of the patient. At the same time, the average levels of this parameter in patients of group I decreased to 2.1±0.7 points, and in Group II they were 3.3±0.4 points.